Comparative Pharmacology
Head-to-head clinical analysis: LEVOCETIRIZINE DIHYDROCHLORIDE versus PROMETHAZINE VC PLAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOCETIRIZINE DIHYDROCHLORIDE versus PROMETHAZINE VC PLAIN.
LEVOCETIRIZINE DIHYDROCHLORIDE vs PROMETHAZINE VC PLAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levocetirizine is a selective antagonist of peripheral histamine H1 receptors, blocking histamine-induced allergic responses by inhibiting H1 receptor activation in the gastrointestinal tract, blood vessels, and respiratory tract.
Promethazine is a phenothiazine derivative with antihistaminic (H1 receptor antagonist), sedative, antiemetic, and anticholinergic effects. Phenylephrine is a sympathomimetic amine acting primarily on alpha-1 adrenergic receptors, causing vasoconstriction.
5 mg orally once daily in the evening.
Adults: 1 tablet (promethazine 6.25 mg, phenylephrine 10 mg) orally every 4-6 hours as needed, not to exceed 4 tablets in 24 hours.
None Documented
None Documented
Terminal elimination half-life: 7-11 hours in adults. Clinically, this supports once-daily dosing; may be prolonged in renal impairment (creatinine clearance <30 mL/min).
Terminal elimination half-life is approximately 9–16 hours (mean ~12 hours) in adults; may be prolonged in hepatic impairment or elderly patients.
Renal: 85% as unchanged drug (70%) and metabolites (15%); fecal: 13%; biliary: minimal (<2%).
Primarily renal as inactive metabolites; approximately 70-80% excreted in urine, with about 20-30% in feces via biliary secretion. Less than 1% excreted unchanged.
Category A/B
Category A/B
Antihistamine
Antihistamine / Antiemetic